High affinity nucleic acid ligands of complement system proteins
AssigneeGilead Sciences, Inc.
InventorsGregory Biesecker, Larry Gold
Life of this patent
Estimating the term…
Abstract
Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
Claims8
A method for treating a Complement System-mediated disease comprising administering a pharmaceutically effective amount of a Nucleic Acid Ligand of a Complement System Protein.
A method of treating a disease comprising:
- a) administering a pharmaceutical agent which specifically treats said disease;
- and
- b) administering a Nucleic Acid Ligand C1q inhibitor in an amount effective to inhibit activation of the Complement System.
A method of treating a bacterial or viral infection comprising:
- a) conjugating a Nucleic Acid Ligand that has been generated to a bacterial cell surface target or viral particle target with a C1q Nucleic Acid Ligand;
- and
- b) administering the conjugate in an amount effective to activate the Complement System and lyse the infected cell.
A method of killing tumor cells in a patient comprising:
- a) conjugating a Nucleic Acid Ligand that has been generated to a tumor cell surface target with a C1q Nucleic Acid Ligand;
- and
- b) administering the conjugate in an amount effective to activate the Complement System and kill the tumor or tumor cell.
Dependencies are inferred from the claim text.